Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aehr Test Systems (AEHR) vs Barclays PLC (BCS) Price & Performance

Aehr Test SystemsTrade
Barclays PLCTrade

Price performance (Past 24H)

Key statistics

Aehr Test Systems vs Barclays PLC — how do they compare? Aehr Test Systems trades at $119.19 (market cap $3.46B), while Barclays PLC trades at $28.01 (market cap $94.10B). The key difference: Barclays PLC is far larger — about 27.2× Aehr Test Systems's market cap, and Barclays PLC pays a 2.18% dividend while Aehr Test Systems pays none. Which is the better fit depends on your goals.

AEHRBCS
Market Cap
$3.46B$94.10B
Sector
TechnologyFinancials
52-Week High
$117.18$28.56
52-Week Low
$17.38$19.36
Enterprise Value
$3.36B
Dividend Yield
2.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aehr Test Systems

AEHR Test Systems trades at $103.07, up 3.34% with strong technical momentum and bullish moving average signals. The company shows improving earnings trends with three consecutive quarterly beats, though profitability remains negative with a -14.25% net margin. Recent news highlights significant silicon photonics orders and a strategic pivot toward AI infrastructure, driving investor optimism despite insider selling activity.

Outlook remains growth-focused with FY27 revenue guidance of 160-200% expansion, though high valuation (P/S 65.13) and customer concentration pose risks. Analyst consensus leans neutral with 33% buy ratings, while technical indicators suggest near-term support at $97 with resistance at $107. The stock's AI-driven backlog expansion supports bullish sentiment despite current negative cash flow.

Barclays PLC

Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.

The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aehr Test Systems

Aehr Test Systems provides testing and burn-in solutions for the semiconductor industry. Its systems ensure the reliability of AI processors, data center chips, and electric vehicle components at the wafer and package levels.

Read more on AEHR

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS